Stem Cell and Senolytic Combo Extends Mouse Lifespan by Over 70%
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Summary
Researchers from Immorta Bio and TAM Global tested a two-pronged treatment in mice combining SenoVax, a therapy that targets and removes aging, dysfunctional cells, with StemCellRevivify, a personalized stem cell treatment designed to restore tissue function. The result was a more than 70 percent increase in lifespan, along with sustained improvements in physical performance. The study involved scientists from leading institutions including the Buck Institute for Research on Aging, Stanford, Cedars-Sinai, and the University of Miami. While the findings are preclinical and require further validation before any human application, the scale of the effect is notable. The companies plan mechanistic follow-up studies and eventual clinical translation, and a full manuscript has been made available.
Detailed Summary
A striking new preclinical result is drawing attention in the longevity research community. Biotechs Immorta Bio and TAM Global announced that their combined therapeutic approach extended mouse lifespan by more than 70 percent, one of the largest lifespan extension results reported in recent years. The study was disclosed June 15, 2026, from Nashville, Tennessee, with scientific contributions from multiple respected institutions.
The treatment involved two complementary strategies. SenoVax is an immune-based therapy designed to selectively identify and clear senescent cells, the damaged, growth-arrested cells that accumulate with age and drive chronic inflammation and tissue dysfunction. StemCellRevivify is a personalized mesenchymal stem cell platform intended to replenish regenerative capacity and restore tissue function lost during aging. Combining these two approaches may address aging from both a removal and restoration angle simultaneously.
Beyond lifespan extension, treated animals showed sustained improvements in physiological performance, suggesting the therapy supports healthspan, not just survival. This distinction matters: living longer without functional decline is the core goal of longevity medicine. The involvement of teams from the Buck Institute, Stanford School of Medicine, Cedars-Sinai, and the University of Miami lends institutional credibility to the collaboration.
The practical implications are significant if findings translate to humans. Senolytic therapies and stem cell interventions are both active areas of clinical investigation, but combining them in a coordinated protocol represents a more ambitious systems-level approach to reversing biological aging. This study suggests synergy between the two modalities may be greater than either alone.
Critical caveats remain. This is a mouse study, and mouse lifespan results have historically failed to translate directly to humans. The announcement is a press release rather than peer-reviewed publication, though the companies state a full manuscript is available. Independent replication and mechanistic clarity will be essential before drawing conclusions about human applicability.
Key Findings
- Combined senolytic and stem cell therapy extended mouse lifespan by over 70% in preclinical testing.
- SenoVax selectively clears senescent cells; StemCellRevivify restores tissue function via personalized mesenchymal stem cells.
- Treated mice showed sustained improvements in physiological performance, indicating healthspan gains alongside lifespan extension.
- Research involved scientists from Buck Institute, Stanford, Cedars-Sinai, and University of Miami.
- Companies plan further mechanistic studies and clinical translation; full manuscript is reportedly available.
Methodology
This is a news report summarizing a company press release from Immorta Bio and TAM Global announcing preclinical mouse study results. The source, Longevity.Technology, is a credible longevity-focused outlet, but the underlying data has not yet appeared in a peer-reviewed journal. A manuscript is stated to be available but has not been independently verified.
Study Limitations
This is a preclinical mouse study and lifespan results in mice frequently do not translate to humans. The announcement originates from a company press release rather than a published, peer-reviewed paper, making independent verification of methodology and effect size essential. Readers should consult the full manuscript and await independent replication before drawing conclusions about therapeutic potential.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.